ArticleJournal of traditional and complementary medicine2026
Kaixuan Qibi granules attenuate myocardial fibrosis through BRD4 blockade regulated by the NF-κB/NLRP3 signaling pathway.
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Kaixuan Qibi granules (KXGs) have exhibited favorable therapeutic outcomes in addressing a wide range of ailments. They have established their efficacy as a traditional Chinese medicine formulation, particularly for cardiovascular and cerebrovascular diseases associated with myocardial fibrosis (MF). Targeting of bromodomain-containing protein 4 (BRD4) represents an efficacious strategy for addressing inflammation (a pivotal factor in MF progression). However, revealing the inhibitory impact of KXGs on BRD4 in MF development is elusive. We investigated the impact of KXGs on MF and elucidated the regulatory mechanism of BRD4 in MF by KXGs Experimental procedure: Induction of an Results: In this study, we observed a notable reduction in the extent of fibrotic tissue accompanied by organized collagen following treatment with KXGs. KXGs exhibited a significant regulatory effect on metabolite levels while also inhibiting BRD4-related pathways and the inflammatory response. Later, KXGs exhibited downregulation the expression of BRD4, phosphorylated (p)-NF-κB p65 (phosphor/total), NLRP3, ASC, caspase-1, and interleukin-1β (IL-1β) in both Conclusion: KXGs attenuated MF progression by modulating the NF-κB/NLRP3 signaling pathway through inhibition of BRD4 activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.